As of 2024-12-13, the EV/EBITDA ratio of GlaxoSmithKline PLC (GSK.L) is 6.15. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. GSK.L's latest enterprise value is 68,313.88 mil GBP. GSK.L's TTM EBITDA according to its financial statements is 11,100.00 mil GBP. Dividing these 2 quantities gives us the above GSK.L EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 6.3x - 9.9x | 7.2x |
| Forward P/E multiples | 15.4x - 19.4x | 18.0x |
| Fair Price | 1,362.78 - 4,578.88 | 2,927.66 |
| Upside | 2.2% - 243.2% | 119.5% |
| Date | EV/EBITDA |
| 2024-12-12 | 6.15 |
| 2024-12-11 | 6.18 |
| 2024-12-10 | 6.30 |
| 2024-12-09 | 6.33 |
| 2024-12-06 | 6.19 |
| 2024-12-05 | 6.18 |
| 2024-12-04 | 6.23 |
| 2024-12-03 | 6.28 |
| 2024-12-02 | 6.18 |
| 2024-11-29 | 6.16 |
| 2024-11-28 | 6.18 |
| 2024-11-27 | 6.19 |
| 2024-11-26 | 6.17 |
| 2024-11-25 | 6.20 |
| 2024-11-22 | 6.18 |
| 2024-11-21 | 6.06 |
| 2024-11-20 | 6.03 |
| 2024-11-19 | 6.04 |
| 2024-11-18 | 6.07 |
| 2024-11-15 | 6.03 |
| 2024-11-14 | 6.23 |
| 2024-11-13 | 6.26 |
| 2024-11-12 | 6.28 |
| 2024-11-11 | 6.39 |
| 2024-11-08 | 6.33 |
| 2024-11-07 | 6.32 |
| 2024-11-06 | 6.29 |
| 2024-11-05 | 6.37 |
| 2024-11-04 | 6.45 |
| 2024-11-01 | 6.47 |
| 2024-10-31 | 6.37 |
| 2024-10-30 | 6.42 |
| 2024-10-29 | 6.59 |
| 2024-10-28 | 6.59 |
| 2024-10-25 | 6.57 |
| 2024-10-24 | 6.60 |
| 2024-10-23 | 6.57 |
| 2024-10-22 | 6.59 |
| 2024-10-21 | 6.63 |
| 2024-10-18 | 6.68 |
| 2024-10-17 | 6.75 |
| 2024-10-16 | 6.75 |
| 2024-10-15 | 6.74 |
| 2024-10-14 | 6.74 |
| 2024-10-11 | 6.69 |
| 2024-10-10 | 6.78 |
| 2024-10-09 | 6.61 |
| 2024-10-08 | 6.59 |
| 2024-10-07 | 6.69 |
| 2024-10-04 | 6.61 |